Overview / Abstract: |
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances in the use of cytogenetic and molecular tests to stratify risk and determine prognosis. |
Expiration |
May 18, 2024 |
Discipline(s) |
Nurse Practitioner , Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
0.75 AMA PRA Category 1 Credit™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Lindsey E. Roeker, MD, MSCE"Program Chair Michael Choi, MD Geoffrey Grubbs"Patient advocate |
Sponsors / Supporters / Grant Providers |
Support for this activity has been provided through educational grants from AbbVie Inc. and AstraZeneca Pharmaceuticals. |
Keywords / Search Terms |
RedMedEd CE, Free, RedMedEd, Chronic lymphocytic leukemia, B cell, Non-Hodgkin’s, Lymphoma, Hematology, Hematologic, Oncology, Inhibitor, Monoclonal, CLL Free CE CME |